Bayesian Pharmacokinetically Guided Dosing of Paclitaxel in Patients with Non-Small Cell Lung Cancer

Clinical Cancer Research

Volumn 10, Issue 7, 2004, Pages 2237-2244

  De Jonge, Milly E ^a   Van Den Bongard, H J G Desirée ^b   Huitema, Alwin D R ^a   Mathôt, Ron A A ^a   Rosing, Hilde ^a   Baas, Paul ^b   Van Zandwijk, Nico ^b   Beijnen, Jos H ^a,b   Schellens, Jan H M ^b  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL; TAXANE DERIVATIVE;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BAYES THEOREM; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG SAFETY; ERYTHEMA; FATIGUE; FEMALE; FEVER; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; PRURITUS; SOLID TUMOR; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BAYES THEOREM; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PACLITAXEL; TIME FACTORS;

EID: 1842426659     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0060     Document Type: Article

References (27)

1. Huizing MT, Sewberath Misser VH, Pieters RC, et al. Taxanes: a new class of antitumor agents. Cancer Investig 1995;13:381-404.
2. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995;332:1004-14.
3. Eisenhauer EA, Ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994;12:2654-66.
4. Novello S, Le Chevalier T. European perspectives on paclitaxel/ platinum-based therapy for advanced non-small cell lung cancer. Semin Oncol 2001;28:3-9.
5. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
6. Huizing MT, Giaccone G, Van Warmerdam LJC, et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and sequencing study in patients with non-small-cell lung cancer. J Clin Oncol 1997;15:317-29.
7. Huizing MT, Keung ACF, Rosing H, et al. Pharmacokinetics of paclitaxel and metabolites in a randomised comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 1993;11:2127-35.
8. Gianni L, Kearns CM, Gianni A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995;13:180-90.
9. Van Den Bongard HJGD. Development and validation of a population pharmacokinetic model of paclitaxel in cancer patients. In: Clinical pharmacokinetics of anticancer agents. Focus on E7070, methotrexate and paclitaxel. Utrecht, the Netherlands: Thesis University Utrecht; 2002. ISBN 90-6734-045-6.
10. De Jonge ME, Huitema ADR, Rodenhuis S, and Beijnen JH. Individualized cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation (Review). Clin Pharmacokinet. In press 2004.
11. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56.
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
13. Leger F, Seronie-Vivien S, Makdessi J, et al. Impact of the biochemical assay for serum creatinine measurement on the individual carboplatin dosing: a prospective study. Eur J Cancer 2002;38:52-6.
14. Willey TA, Bekos EJ, Gaver RC, et al. High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma. J Chromatogr 1993;621:231-8.
15. Huizing MT, Sparreboom A, Rosing H, Van Tellingen O, Pinedo HM, Beijnen JH. Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography. J Chromatogr B 1995;674:261-8.
16. Van Warmerdam LJC, Van Tellingen O, Maes RAA, Beijnen JH. Validated method for the determination of carboplatin in biological fluids by Zeeman atomic absorption spectrometry. Fresenius J Anal Chem 1995;351:1820-4.
17. Beal SL and Sheiner LB. NONMEM Users Guides, NONMEM Project Group. San Francisco: University of California at San Francisco; 1998.
18. Guidelines for Reporting of Adverse Drug Reactions. Bethesda, Maryland: National Cancer Institute, Division of Cancer Treatment; 1988.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst (Bethesda) 2000;92:205-16.
20. Karlsson MO, Molnar V, Freijs A, Nygren P, Bergh J, Larsson R. Pharmacokinetic models for the saturable distribution of paclitaxel. Drug Metab Dispos 1999;37:266-70.
21. Van Tellingen O, Huizing MT, Nannan Panday VR, Schellens JHM, Nooijen WJ, Beijnen JH. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 1999;81: 330-5.
22. Sparreboom A, Van Tellingen O, Nooijen WJ, Beijnen JH. Non-linear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 1996;56:2112-5.
23. Sparreboom A, Van Zuylen L, Brouwer E, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999;59:1454-7.
24. Van Zuylen L, Karlsson MO, Verweij J, et al. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother Pharmacol 2001;47:309-18.
25. Van Zuylen L, Gianni L, Verweij J, et al. Inter-relationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients. Anti-Cancer Drugs 2000;11:331-7.
26. Henningsson A, Karlsson MO, Viganò L, Gianni L, Verweij J, Sparreboom A. Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol 2001;19:4065-73.
27. Henningsson A, Sparreboom A, Sandström M, et al. Population pharmacokinetic modeling of unbound and total plasma concentrations of paclitaxel in cancer patients. Eur J Cancer 2003;39:1105-14.